Global Blood Therapeutics, Inc.

ACTIVE

181 Oyster Point Blvd, South San Francisco, California, United Stateswww.gbt.comPublic457 employeesEstablished: 2011-02-01

Also known as:

gbt

global blood therapeutics, inc, a subsidiary of pfizer inc.

Part of PFIZER INC.

Clinical Trials

27 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2011

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

63.9%

Phase 3

25.0%

Phase 2

8.3%

Trial Status Distribution

Active, not recruiting

63.9%

Completed

11.1%

Not yet recruiting

11.1%

Recruiting

8.3%

Suspended

2.8%

Unknown

2.8%

Clinical Trials

Trials sponsored by this organization (36)

Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

Phase 2

Completed

interventional

Jun 202438 participants

A Phase 2/3 Study in Adult and Pediatric Participants with SCD

Phase 1

Active, not recruiting

interventional

Apr 2024229 participants

A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease

Phase 2

Not yet recruiting

interventional

Feb 2023480 participants

Open-Label Extension of Voxelotor

Phase 3

Not yet recruiting

interventional

Oct 202221 participants

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Phase 3

Recruiting

interventional

Jun 2022280 participants

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises

Phase 3

Recruiting

interventional

May 2022240 participants

An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial

Phase 3

Not yet recruiting

interventional

Feb 2022520 participants

A Phase 2/3 Study in Adult and Pediatric Participants with Sickle Cell Disease (SCD)

Phase 2

Not yet recruiting

interventional

Oct 2021480 participants

Page 1 of 5

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

Recent Approvals

News

No news articles found

Back to Organizations